Drug profile · INN
nirogacestat hydrobromide
OGSIVEO
nirogacestat hydrobromide (OGSIVEO) is a gamma-secretase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — nirogacestat hydrobromide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
nirogacestat hydrobromide (OGSIVEO) is a gamma-secretase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Gamma-secretase inhibitor
Primary target: Gamma-secretase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is nirogacestat hydrobromide?
nirogacestat hydrobromide (OGSIVEO) is a gamma-secretase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for nirogacestat hydrobromide?
OGSIVEO is a marketed brand name for nirogacestat hydrobromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nirogacestat hydrobromide?
nirogacestat hydrobromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.